Clinical trials: Remitting-Relapsing Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis
PET with [18F]Flumazenil As an Index of Neurodegeneration in MS
Beyond white matter pathology, grey matter damage is considered as a key player in disability onset and progression in Multiple Sclerosis (MS).
- Trial name
- FLUMA-SEP-T (NCT03825601)
- Testing
- PET with [11C]Flumazenil
- Where
- France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Relapsing Remitting Multiple Sclerosis
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
In this study the investigators wish to test the hypothesis that the repertoire of solutes secreted by leukocytes isolated from patients with relapsing-remitting forms of Multiple Sclerosis (MS) following 6 months of treatment…
- Trial name
- NCT05171972
- Testing
- Ofatumumab
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Multiple Sclerosis
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and…
- Trial name
- NCT00819195
- Testing
- Glatiramer acetate
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Multiple Sclerosis, Covid19
MS Relapses During COVID-19 Pandemic
Throughout the COVID-19 pandemic, and to our knowledge there have been no studies looking systematically at the occurrence of MS relapses and their subsequent management, during the peak of the first wave of the pandemic.
- Conditions
- Multiple Sclerosis, Covid19, Relapsing Remitting Multiple Sclerosis
- Trial name
- NCT04858763
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Nottingham University Hospitals NHS Trust
Multiple Sclerosis, Relapsing-Remitting
Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis
Multiple Sclerosis (MS) is the most common acquired neurological disease leading to disability, especially ambulatory, in young adults.
- Trial name
- MS-TRACTS (NCT04220814)
- Testing
- MRI, Electrophysiology
- Where
- 2 sites in France
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Central Nervous System (CNS) demyelinating conditions include multiple sclerosis (MS), Acute Disseminated Encephalomyelitis (ADEM), Neuromyelitis Optica Spectrum Disorder (NMOSD), Optic Neuritis (ON) and Transverse Myelitis (TM).
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Transverse Myelitis
- Trial name
- SONICS (NCT03942952)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Relapsing Remitting Multiple Sclerosis
Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple
1.to evaluate the potential role of the optic nerve diameter ( OND determined by ultrasonography and and visual nerve function by visual evoked potential as a biomarker of early axonal loss and disability in patients with…
- Trial name
- NCT06435962
- Testing
- sonography
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Multiple Sclerosis, Relapsing-Remitting
Cognition and MRI Markers in MS Patients With Aubagio® Treatment
Cognitive impairment is nowadays more and more recognized as an important feature of the multiple sclerosis (MS) disease which contributes largely to disability.
- Trial name
- AUBACOG (NCT03768648)
- Testing
- Clinical assessment, Ecological evaluation, Neuropsychological evaluation
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Multiple Sclerosis, Relapsing-Remitting
Phase I BP Interferon (IFN) Beta-001
Phase I study aiming at: assessing the absolute bioavailability, pharmacokinetic profile, and dose proportionality of interferon beta-1a (HSA-free solution in pre-filled syringes) after i.v. and s.c.
- Trial name
- NCT02515695
- Testing
- Interferon beta-1a
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Cognition, Brain Volume Loss
Effect of Fingolimod on Neurodegeneration
This was a 24-month, open-label, multicenter study with a single treatment arm design. Primary objective of this study was: -To investigate the effects of Fingolimod on cognitive performance in highly active relapsing remitting…
- Trial name
- NCT02575365
- Testing
- 0,5 mg Fingolimod
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis (MS) - Relapsing-remitting
Deuterium Metabolic Imaging in People with Multiple Sclerosis
The goal of this case-control study is to investigate glucose brain metabolism in people with multiple sclerosis and age- and sex-matched healthy controls.
- Trial name
- NCT06611280
- Testing
- No Interventions
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Multiple Sclerosis, Relapsing-Remitting, Optic Neuritis
Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis
Multiple sclerosis (MS) affects approximately 2.3 million patients worldwide, with a global median prevalence of 33 per 100,000. MS is diagnosed at an average of 30 years and affects twice as many women as men.
- Trial name
- NCT03401879
- Testing
- Dynamic Vessel Analyzer (DVA), Fourier Domain Doppler Optical Coherence Tomography (FDOCT), Optical coherence tomography (OCT)
- Where
- Austria
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna